Could it be $$ related NB? Whats the point of finishing the trial if its solely because of poor efficacy? Maybe agile themselves are feeling the $$$ pinch and require $$$ from drug candidates.. when you look back at Novogen mk1 - they pulled the trial on Phenoxodol/Idronoxil before completing it as from memory they didn't see the sense in spending more completing it. This appears to have caught KZA by surprise as well as us but without knowing the reasoning other than its not going forward in that particular trial to the next stage we have next to zero..
